REPL Replimune Group, Inc.

NASDAQ
$12.36

Replimune Group, Inc. (REPL) is expected to report earnings on November 9, 2026, before the market open. The consensus earnings estimate is a loss of $0.70 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -18.6% since its last earnings release on August 14, 2026.

Replimune Group Reported In-line with Estimates
Friday, August 14, 2026 · 8:00 AM ET
Earnings Date
2nd Quarter, Sep 2026
Nov 9
Monday · 8:00 AM ET
Earnings Whisper
-
vs ($0.70)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $14.37

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Replimune Group, Inc.

Replimune Group, Inc. was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.